At 7.8% CAGR, Asia Pacific Infusion Devices Market is Projected to be Worth US$ 5,490.48 Million by 2031, says The Insights Partners

According to The Insights Partners research, the Asia Pacific infusion devices market was valued at US$ 3,014.20 million in 2023 and is expected to reach US$ 5,490.48 million by 2031, registering a CAGR of 7.8% from 2023 to 2031. Growing geriatric population and increasing prevalence of cancer are among the critical factors attributed to driving the Asia Pacific infusion devices market growth.

Advancements in healthcare are increasing life expectancy globally, leading to a global rise in the geriatric population. As per the WHO, by 2030, one in 6 people in the world will be 60 years or more. One billion people were reported to be 60 and above in 2020 and the number is expected to reach 1.4 billion in 2030 and 2.1 billion by 2050. WHO also stated that by 2050, 80% of older people will be living in low- and middle-income countries. Additionally, as per the Population Reference Bureau, Asia and Europe have the oldest population. Japan ranks first with 28% of geriatric population, followed by Italy with 23%. Finland, Portugal, and Greece are among the top five countries with ~22% of geriatric population. A few key benefits of infusion therapy used for geriatric populations are listed below.

Rehydration and Electrolyte Balance: Dehydration can be a higher risk for older people due to factors such as decreased urge to drink fluids, certain medications, and changes in kidney function. IV fluids help seniors maintain the necessary hydration and electrolyte levels for overall health.

Improved Nutritional Status: Consumption and absorption of the required nutrient become challenging with age, increasing the risk of chronic illnesses. Infusion therapy provides essential minerals, vitamins, and amino acids efficiently into the bloodstream and eases the process of nutrient uptake.

Enhanced Immune Function: Immune systems need extra support at an older age as they become more vulnerable to infections. Infusion therapy can deliver immune-boosting nutrients such as vitamin C, zinc, and glutathione directly to the body.

Pain Management: The senior population majorly suffers from chronic pain, affecting their quality of life. Infusion therapy can quickly and effectively manage pain by delivering medication directly into the bloodstream, reducing inflammation and providing relief.

Thus, the increasing geriatric population drives the demand for infusion devices across the globe.

On the contrary, frequent product recalls of infusion devices hamper the growth of Asia Pacific infusion devices market.

By product type, the Asia Pacific infusion devices market is bifurcated into infusion pumps and infusion sets. The infusion pumps held 75.2% share of Asia Pacific infusion devices market share in 2023, amassing US$ 2,265.24 million. It is projected to garner US$ 4,181.59 million by 2031 to register 8.0% CAGR during 2023-2031.

In terms of infusion pumps, the market is segmented into volumetric pumps, syringe pumps, insulin pumps, patient control analgesia (PCA) pumps, enteral pumps, implantable pumps, and elastomeric pumps. The volumetric pumps segment held a 29.0% share of Asia Pacific infusion devices market share in 2023, amassing US$ 656.97 million. It is projected to garner US$ 1,175.27 million by 2031 to register 7.5% CAGR during 2023-2031.

By infusion sets, the Asia Pacific infusion devices market is bifurcated into vented infusion sets and non-vented infusion sets. The vented infusion sets held 61.2% share of Asia Pacific infusion devices market share in 2023, amassing US$ 458.09 million. It is projected to garner US$ 818.82 million by 2031 to register 7.5% CAGR during 2023-2031.

By application, the Asia Pacific infusion devices market is segmented into diabetes, oncology, pain management, hematology, pediatrics, gastroenterology, and others. The diabetes held a 37.5% share of Asia Pacific infusion devices market share in 2023, amassing US$ 1,131.18 million. It is projected to garner US$ 2,143.55 million by 2031 to register 8.3% CAGR during 2023-2031.

By end user, the Asia Pacific infusion devices market is segmented into hospitals and specialty clinics, homecare settings, ambulatory surgical centers, and others. The hospitals and specialty clinics held a 53.8% share of Asia Pacific infusion devices market share in 2023, amassing US$ 1,621.15 million. It is projected to garner US$ 2,936.11 million by 2031 to register 7.7% CAGR during 2023-2031.

Based on country, the Asia Pacific infusion devices market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 27.4% share of Asia Pacific infusion devices market in 2023. It was assessed at US$ 825.23 million in 2023 and is likely to hit US$ 1,552.24 million by 2031, registering a CAGR of 8.2% during 2023-2031.

Key players operating in the infusion devices market are B Braun SE, Baxter International Inc, Becton Dickinson and Co, BPL Medical Technologies Pvt Ltd, CODAN US Corp, Eitan Medical Ltd, Elimedical Inc, Fresenius Kabi AG, ICU Medical Inc, KD Scientific Inc, Medtronic Plc, Moog Inc, Nipro Corp, Polymedicure, Tandem Diabetes Care Inc, Terumo Corp, and Zimed Healthcare Ltd, among others.

- In May-2024: Moog Inc. received US FDA 510(k) clearance for CURLIN 8000 Ambulatory Infusion System. This premium infusion platform was developed specifically for use in home infusion settings. The CURLIN 8000 combines a reliable and robust design with a simple, intuitive user interface designed for easy navigation by both clinical and non-clinical users. The CURLIN 8000 also integrates seamlessly with CURLIN RxManager, a completely new medication safety software developed to complement existing home infusion workflows.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com